Nivalis Therapeutics, Inc. (NVLS) is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates through discovering and development of potential drugs segment. Its operations are focused on discovery and development of its portfolio of GSNOR inhibitors, including N91115. Its product candidate, N91115, is a small molecule compound that addresses a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) resulting from mutations in the CFTR gene, the underlying cause of CF. The Company is conducting a Phase II clinical trial designed to demonstrate the safety of a triple therapy of N91115 along with lumacaftor/ivacaftor in over 130 adult CF patients homozygous for F508del.
Down 53% after hours on news below Nivalis Therapeutics (NVLS) Announces Cavosonstat Phase 2 in CF Missed Primary Endpoint Source: http://www.streetinsider.com/Corpor...2+in+CF+Missed+Primary+Endpoint/12287843.html
Oh painful! This is the thing about biotechs, you can hit massive jackpots by being in at the right time, or you can wake up one morning and find yourself down 50%.
